Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | 10% owner | August 07, 2023 | August 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MIRA PHARMACEUTICALS, INC.
Report date August 07, 2023 · Filed August 24, 2023
Jointly reported with Bay Shore Trust
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,859,318 |
Reported balance
After 2023-08-07 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-08-07 · Purchase · Acquired 119,048 · Balance 2,859,318 F1: These securities are owned directly by the Bay Shore Trust (the "Trust"), a greater-than-10% owner of the Issuer. As sole trustee of the Trust, George Cappy ("Mr. Cappy") has sole ownership and dispositive power over these securities and is therefore deemed to be an indirect beneficial owner of the securities for purposes of SEC Rule 13d-3, although Mr. Cappy disclaims beneficial ownership of the reported securities due to the absence of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2023-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F2: These securities are owned directly by Mr. Cappy. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are owned directly by the Bay Shore Trust (the "Trust"), a greater-than-10% owner of the Issuer. As sole trustee of the Trust, George Cappy ("Mr. Cappy") has sole ownership and dispositive power over these securities and is therefore deemed to be an indirect beneficial owner of the securities for purposes of SEC Rule 13d-3, although Mr. Cappy disclaims beneficial ownership of the reported securities due to the absence of any pecuniary interest therein.
F2: These securities are owned directly by Mr. Cappy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2023 Filed Aug 24, 2023 21:38 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 119,048 | $7.00 | $833,336.00 |
DisclosureSEC source: 0000897069-23-001265 · form4.xml · nonDerivative · entry 1 Cappy George · CIK 0001986372 · 10% owner Bay Shore Trust · CIK 0001986593 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,859,318 F1 · ownership.nature: These securities are owned directly by the Bay Shore Trust (the "Trust"), a greater-than-10% owner of the Issuer. As sole trustee of the Trust, George Cappy ("Mr. Cappy") has sole ownership and dispositive power over these securities and is therefore deemed to be an indirect beneficial owner of the securities for purposes of SEC Rule 13d-3, although Mr. Cappy disclaims beneficial ownership of the reported securities due to the absence of any pecuniary interest therein. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 17:42 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | PurchaseCommon Stock | 157,170 | $7.00 | $1,100,190.00 |
DisclosureSEC source: 0000897069-23-001091 · form4.xml · nonDerivative · entry 1 Cappy George · CIK 0001986372 · 10% owner Bay Shore Trust · CIK 0001986593 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,740,270 F1 · kind: Represents the acquisition of shares of common stock by the Bay Shore Trust (the "Trust") through the conversion of an aggregate of $1,100,190 of indebtedness owing by the Issuer to the Trust, with such conversion occurring on the date of the Issuer's initial public offering at a conversion price of $7.00 per share. F2 · ownership.nature: These securities are owned directly by the Trust, a greater-than-10% owner of the Issuer. As sole trustee of the Trust, George Cappy ("Mr. Cappy") has sole ownership and dispositive power over these securities and is therefore deemed to be an indirect beneficial owner of the securities for purposes of SEC Rule 13d-3, although Mr. Cappy disclaims beneficial ownership of the reported securities due to the absence of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.